A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal

Autor: Yuichi Ando, Sachi Morita, Tomoya Shimokata, Toyonori Tsuzuki, Shigeru Inafuku, Kenichiro Iwami, Nicoletta Brega, Takashi Akagawa, Toshiaki Tsujino, Tetsuya Ogawa

Publikováno v: International Cancer Conference Journal. 11:242-246

For decades, no clear consensus existed on the standard treatment option for malignant tumors of the external auditory canal, an extremely rare disease. Here we report the case of a 55-year-old female patient with secretory carcinoma that originated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ee01e98dd4eb66202f36031fca6e191
https://doi.org/10.1007/s13691-022-00559-6

Data from A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Autor: Giuseppe Giaccone, Nicoletta Brega, Michael Shnaidman, Brett E. Houk, William D. Figg, Baskar Mannargudi, Lokesh Jain, Wadih M. Zein, Sonja Crandon, Martin Gutierrez, Shivaani Kummar, Sylvia V. Alarcon, Yeong Sang Kim, Jane B. Trepel, Ronan J. Kelly, Arun Rajan

Purpose: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas.Methods: This was a single-institution,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9137d38582dab3191c2b0638950622b6
https://doi.org/10.1158/1078-0432.c.6519831.v1

Abstract CT228: Concordance between tissue and circulating tumor DNA (ctDNA) testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusions in larotrectinib (laro) clinical trials

Autor: Erin R. Rudzinski, Marc Ladanyi, Lauren L. Ritterhouse, Felix Sahm, Ricarda Norenberg, Hong Zheng, Chi Chen, Vadim Bernard-Gauthier, Nicoletta Brega, Cornelis M. van Tilburg, Jessica J. Lin, Marcia S. Brose, Ulrik N. Lassen, Ray McDermott, Theodore W. Laetsch, David S. Hong, Alexander Drilon, Sinchita Roy-Chowdhuri

Publikováno v: Cancer Research. 83:CT228-CT228

Background: NTRK gene fusions are oncogenic drivers in various tumor types. Laro, a highly selective and central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor, is approved for the treatment of patients (pts) with TRK fusion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b5c3a1927c36dfdf70eef05368cb7680
https://doi.org/10.1158/1538-7445.am2023-ct228

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

Autor: Alexander Drilon, Daniel S. W. Tan, Ulrik N. Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D. Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Lin Shen, Victor Moreno, Shivaani Kummar, Jessica J. Lin

Publikováno v: Drilon, A, Tan, D S W, Lassen, U N, Leyvraz, S, Liu, Y, Patel, J D, Rosen, L, Solomon, B, Norenberg, R, Dima, L, Brega, N, Shen, L, Moreno, V, Kummar, S & Lin, J J 2022, ' Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers ', JCO Precision Oncology, vol. 6, e2100418 . https://doi.org/10.1200/PO.21.00418

PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type. The aim of this study was to assess the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc1b3ac2b9e98e4444d601a84aaed822
https://doi.org/10.1200/po.21.00418

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Autor: Steven G Waguespack, Alexander Drilon, Jessica J Lin, Marcia S Brose, Ray McDermott, Mohammed Almubarak, Jessica Bauman, Michela Casanova, Anuradha Krishnamurthy, Shivaani Kummar, Serge Leyvraz, Do-Youn Oh, Keunchil Park, Davendra Sohal, Eric Sherman, Ricarda Norenberg, Josh D Silvertown, Nicoletta Brega, David S Hong, Maria E Cabanillas

Publikováno v: European journal of endocrinology. 186(6)

Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b38c31972f1ff3e4cc313202f7fdc1a
https://pubmed.ncbi.nlm.nih.gov/35333737